Recurrence‐associated gene signature optimizes recurrence‐free survival prediction of colorectal cancer
Open Access
- 23 September 2017
- journal article
- research article
- Published by Wiley in Molecular Oncology
- Vol. 11 (11) , 1544-1560
Abstract
High throughput gene expression profiling has showed great promise in providing insight into molecular mechanisms. Metastasis‐related mRNAs may potentially enrich genes with the ability to predict cancer recurrence, therefore we attempted to build a recurrence‐associated gene signature to improve prognostic prediction of colorectal cancer (CRC). We identified 2848 differentially expressed mRNAs by analyzing CRC tissues with or without metastasis. For the selection of prognostic genes, a LASSO Cox regression model (least absolute shrinkage and selection operator method) was employed. Using this method, a 13‐mRNA signature was identified and then validated in two independent Gene Expression Omnibus cohorts. This classifier could successfully discriminate the high‐risk patients in discovery cohort [hazard ratio (HR) = 5.27, 95% confidence interval (CI) 2.30–12.08, P < 0.0001). Analysis in two independent cohorts yielded consistent results (GSE14333: HR = 4.55, 95% CI 2.18–9.508, P < 0.0001; GSE33113: HR = 3.26, 95% CI 2.16–9.16, P = 0.0176). Further analysis revealed that the prognostic value of this signature was independent of tumor stage, postoperative chemotherapy and somatic mutation. Receiver operating characteristic (ROC) analysis showed that the area under ROC curve of this signature was 0.8861 and 0.8157 in the discovery and validation cohort, respectively. A nomogram was constructed for clinicians, and did well in the calibration plots. Furthermore, this 13‐mRNA signature outperformed other known gene signatures, including oncotypeDX colon cancer assay. Single‐sample gene‐set enrichment analysis revealed that a group of pathways related to drug resistance, cancer metastasis and stemness were significantly enriched in the high‐risk patients. In conclusion, this 13‐mRNA signature may be a useful tool for prognostic evaluation and will facilitate personalized management of CRC patients.Keywords
Funding Information
- National Natural Science Foundation of China (81421001, 81320108024, 31371420, 81530072, 81402347, 81602518, 31371273)
- Shanghai Municipal Education Commission
- Shanghai Municipal Education Commission (20161309)
- Shanghai Jiao Tong University
This publication has 77 references indexed in Scilit:
- A DNA Repair Pathway–Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based ChemotherapyJNCI: Journal of the National Cancer Institute, 2012
- Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancerGut, 2011
- Genomic and Epigenomic Integration Identifies a Prognostic Signature in Colon CancerClinical Cancer Research, 2011
- Protein Tyrosine Phosphatase PTPN14 Is a Regulator of Lymphatic Function and Choanal Development in HumansThe American Journal of Human Genetics, 2010
- Experimentally Derived Metastasis Gene Expression Profile Predicts Recurrence and Death in Patients With Colon CancerGastroenterology, 2010
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature, 2009
- Twenty-one-base-pair insertion polymorphism creates an enhancer element and potentiates SLC6A1 GABA transporter promoter activityPharmacogenetics and Genomics, 2009
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005
- Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimationStatistics in Medicine, 2004
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002